Literature DB >> 21458900

Albuminuria, proteinuria, and novel urine biomarkers as predictors of long-term allograft outcomes in kidney transplant recipients.

Ferdau L Nauta1, Stephan J L Bakker, Wim van Oeveren, Gerjan Navis, Jaap J Homan van der Heide, Harry van Goor, Paul E de Jong, Ron T Gansevoort.   

Abstract

BACKGROUND: Proteinuria is an established marker of decreased kidney function after kidney transplant. It recently has been suggested that albuminuria might be a more reliable marker. Although albuminuria often is regarded as a marker of glomerular damage, because chronic renal allograft damage is believed to be predominantly an interstitial process, albuminuria in this case might reflect tubular damage. Accordingly, we investigated the value of albuminuria, proteinuria, and tubular damage markers (KIM-1 [kidney injury molecule 1], NAG [N-acetyl-β-d-glucosaminidase], NGAL [neutrophil gelatinase-associated lipocalin], and H-FABP [heart fatty acid binding protein]) in predicting graft outcome in kidney transplant recipients. STUDY
DESIGN: Prospective observational cohort study. SETTING & PARTICIPANTS: 606 patients visiting our outpatient kidney transplant clinic in 2001-2003 were included and used in the analysis for death-censored graft failure. Median follow-up was 4.7 (25th-75th percentile, 3.8-5.2) years. 577 patients had follow-up longer than 1 year and were included in the analysis for estimated glomerular filtration rate (eGFR) decrease. Median follow-up was 3.2 (25th-75th percentile, 2.7-3.7) years. PREDICTORS: Urine protein, albumin, and tubular damage markers in 24-hour urine samples. OUTCOMES: Death-censored graft failure and decrease in eGFR.
RESULTS: There were 42 patients with graft failure; mean eGFR change was -0.46 ± 3.7 (standard deviation) mL/min/1.73 m(2)/y. The area under the receiver operating characteristic curve for death-censored graft failure showed that albuminuria (0.78; 95% CI, 0.59-0.76) was significantly higher than proteinuria (0.67; 95% CI, 0.59-0.76; P = 0.001), NGAL (0.63; 95% CI, 0.52-0.74; P = 0.02), and H-FABP (0.62; 95% CI, 0.53-0.73; P = 0.005) and not significantly different from KIM-1 (0.74; 95% CI, 0.66-0.82) and NAG (0.75; 95% CI, 0.67-0.83). Results were similar for the eGFR decrease outcome. LIMITATIONS: Single-center observational study.
CONCLUSIONS: Measuring albuminuria may provide superior predictions for long-term renal outcomes after kidney transplant than total proteinuria. Additional assessment of urinary excretion of tubular damage markers may have limited value.
Copyright © 2011 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21458900     DOI: 10.1053/j.ajkd.2010.12.022

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  28 in total

1.  Association between peritransplant kidney injury biomarkers and 1-year allograft outcomes.

Authors:  Isaac E Hall; Mona D Doshi; Peter P Reese; Richard J Marcus; Heather Thiessen-Philbrook; Chirag R Parikh
Journal:  Clin J Am Soc Nephrol       Date:  2012-06-21       Impact factor: 8.237

2.  Urinary kidney injury molecule 1 (KIM-1) and interleukin 18 (IL-18) as risk markers for heart failure in older adults: the Health, Aging, and Body Composition (Health ABC) Study.

Authors:  Todd H Driver; Ronit Katz; Joachim H Ix; Jared W Magnani; Carmen A Peralta; Chirag R Parikh; Linda Fried; Anne B Newman; Stephen B Kritchevsky; Mark J Sarnak; Michael G Shlipak
Journal:  Am J Kidney Dis       Date:  2014-03-18       Impact factor: 8.860

3.  Safety and efficacy of administering the maximal dose of candesartan in renal transplant recipients.

Authors:  Masayoshi Okumi; Noritaka Kawada; Naotsugu Ichimaru; Harumi Kitamura; Toyofumi Abe; Ryoichi Imamura; Yasuyuki Kojima; Yukito Kokado; Yoshitaka Isaka; Hiromi Rakugi; Norio Nonomura; Toshiki Moriyama; Shiro Takahara
Journal:  Clin Exp Nephrol       Date:  2011-08-05       Impact factor: 2.801

4.  Chapter 1: Definition and classification of CKD.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2013-01

5.  Urinary kidney injury molecule-1 and the risk of cardiovascular mortality in elderly men.

Authors:  Axel C Carlsson; Anders Larsson; Johanna Helmersson-Karlqvist; Lars Lind; Erik Ingelsson; Tobias E Larsson; Matteo Bottai; Johan Sundström; Johan Ärnlöv
Journal:  Clin J Am Soc Nephrol       Date:  2014-06-12       Impact factor: 8.237

6.  A new clinical prediction tool for 5-year kidney transplant outcome.

Authors:  Colin R Lenihan; Joseph B Lockridge; Jane C Tan
Journal:  Am J Kidney Dis       Date:  2014-04       Impact factor: 8.860

7.  Albuminuria and Allograft Failure, Cardiovascular Disease Events, and All-Cause Death in Stable Kidney Transplant Recipients: A Cohort Analysis of the FAVORIT Trial.

Authors:  Daniel E Weiner; Meyeon Park; Hocine Tighiouart; Alin A Joseph; Myra A Carpenter; Nitender Goyal; Andrew A House; Chi-Yuan Hsu; Joachim H Ix; Paul F Jacques; Clifton E Kew; S Joseph Kim; John W Kusek; Todd E Pesavento; Marc A Pfeffer; Stephen R Smith; Matthew R Weir; Andrew S Levey; Andrew G Bostom
Journal:  Am J Kidney Dis       Date:  2018-07-20       Impact factor: 8.860

8.  Glomerular and tubular damage markers in individuals with progressive albuminuria.

Authors:  Ferdau L Nauta; Lieneke Scheven; Esther Meijer; Wim van Oeveren; Paul E de Jong; Stephan J L Bakker; Ron T Gansevoort
Journal:  Clin J Am Soc Nephrol       Date:  2013-03-28       Impact factor: 8.237

9.  Proteinuria as a Noninvasive Marker for Renal Allograft Histology and Failure: An Observational Cohort Study.

Authors:  Maarten Naesens; Evelyne Lerut; Marie-Paule Emonds; Albert Herelixka; Pieter Evenepoel; Kathleen Claes; Bert Bammens; Ben Sprangers; Björn Meijers; Ina Jochmans; Diethard Monbaliu; Jacques Pirenne; Dirk R J Kuypers
Journal:  J Am Soc Nephrol       Date:  2015-07-07       Impact factor: 10.121

Review 10.  Proteomics and metabolomics in renal transplantation-quo vadis?

Authors:  Rahul Bohra; Jacek Klepacki; Jelena Klawitter; Jost Klawitter; Joshua M Thurman; Uwe Christians
Journal:  Transpl Int       Date:  2012-11-21       Impact factor: 3.782

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.